Loading patent…
AssigneeActinium Pharmaceuticals, Inc.
InventorsMark Berger, Keisha Thomas, Sandesh Seth, Dale Lincoln Ludwig
Estimating the term…
This invention provides a method for depleting a subject's immune cells, where the method includes administering to the subject an effective amount of a radiolabeled anti-CD45 antibody. This invention also provides a method for treating a subject afflicted with cancer, where the method includes (i) administering to the subject an amount of a radiolabeled anti-CD45 antibody effective to deplete the subject's lymphocytes, and (ii) after a suitable time period, performing adoptive cell therapy on the subject to treat the subject's cancer. Finally, this invention provides an article of manufacture including (a) a radiolabeled anti-CD45 antibody, and (b) a label instructing the user to administer to a subject an amount of the antibody effective to deplete the subject's immune cells.
A method for depleting a subject's immune cells, comprising:
The method of claim 3, wherein the effective amount of the radiolabeled anti-CD45 antibody does not induce myeloablation in the subject.
An article of manufacture comprising (a) a radiolabeled anti-CD45 antibody, and (b) a label instructing the user to administer to a subject an amount of the antibody effective to deplete the subject's immune cells, wherein the subject's immune cells comprise any of lymphocytes, regulatory T cells, myeloid derived suppressor cells, tumor associated macrophages, activated macrophages, and combinations thereof.
Dependencies are inferred from the claim text.